Browsing O - Articles científics by Title

Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial

Dijkstra, Esmée; Hospers, Geke; Meershoek-Klein Kranenbarg, Elma; Fleer, Joke; Roodvoets, Annet; Bahadoer, Renu Ragini; Capdevila Castillon, Jaume (Elsevier, 2022-06)

Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice

Laquente, Berta; Macarulla Mercadé, Teresa; Cristina Bugés; Martín, Marta; García, Carlos; Pericay, Carles; Verdaguer Mata, Helena (BMC, 2020-07-10)

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

Kopetz, Scott; Grothey, Axel; Van Cutsem, Eric; Yaeger, Rona; Wasan, Harpreet; Tabernero Caturla, Josep; Yoshino, Takayuki (Elsevier, 2022-06)

Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study

Van Cutsem, Eric; Valderrama, A.; Fuchs, Charles; Shitara, Kohei; Janjigian, Yelena; Alsina Maqueda, Maria; Bang, Yung-Jue (Elsevier, 2021-08)

Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer

Casanova Salas, Irene; Athie Cuervo, Alejandro; Boutros, Paul C.; Del Re, Marzia; Miyamoto, David T.; Pienta, Kenneth J.; Mateo Valderrama, Joaquim (Elsevier, 2021-06)

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

Kramer, Claire; Yaniz-Galende, Elisa; Pellegrino, Benedetta; ter Haar, Natalja; Llop-Guevara, Alba; Herencia Ropero, Andrea; Serra, Violeta (Wiley, 2023-11)

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Compadre, Amanda; van Biljon, Lillian; Valentine, Mark; Graham, Emily; Fashemi, Bisiayo; Herencia Ropero, Andrea; Llop-Guevara, Alba; Serra, Violeta (American Association for Cancer Research, 2023-07-01)

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

Ramlee, Syafiq; Hulse, David; Bernatowicz, Kinga; Pérez López, Raquel; Sala, Evis; Aloj, Luigi (MDPI, 2022-07-27)

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

Carles Galceran, Joan; Mellado, Begoña; Méndez-Vidal, María J.; Vázquez, Sergio; Gonzalez-del-Alba, Aranzazu; Morales Barrera, Rafael; Alonso-Gordoa, Teresa (Elsevier, 2022-09)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Heidenreich, Axel; Gillessen, Silke; Heinrich, Daniel; Keizman, Daniel; O'Sullivan, Joe M; Carles Galceran, Joan (BMC, 2019-01-07)

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Besse, Benjamin; Garcia Campelo, Rosario; cobo, manuel; Mascaux, C; Madroszyk, Anne; FELIP, ENRIQUETA (Elsevier, 2023-09-11)

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Aparicio, Jorge; Virgili Manrique, Anna Cristina; Muñoz Boza, Félix; Galván, Patricia; Richart, Paula; Hernando Cubero, Jorge; Capdevila Castillon, Jaume (Springer, 2022-11)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

Choueiri, T.; Suárez Rodríguez, Cristina; Hainsworth, John; Voog, Eric; Duran, Ignacio; Porta, Camillo (Oxford University Press, 2022-12)

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Van Cutsem, Eric; Tempero, Margaret A.; Sigal, Darren; Fazio, Nicola; Macarulla Mercadé, Teresa; Oh, Do-Youn (American Society of Clinical Oncology, 2020-09-20)

Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)

Bergas, Alba; Albasanz Puig, Adaia; Fernández-Cruz, Ana; Machado, Marina; Novo, Andrés; van Duin, David; Ruiz- Camps, Isabel; Aguilar-Company, Juan (American Society for Microbiology, 2022-06)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Pascual, Cristina; Mingot Castellano, María Eva; Kerguelen Fuentes, Ana Esther; García-Arroba Peinado, José; Cid, Joan; Jiménez, Moraima; VALCARCEL, DAVID (American Society of Hematology, 2022-12-27)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

IACOBONI, GLORIA; Rejeski, Kai; Villacampa Javierre, Guillermo; van Doesum, Jaap; CHIAPPELLA, ANNALISA; Bonifazi, Francesca; Camacho-Arteaga, Lina ; Marin Niebla, Ana; Barba, Pere (American Society of Hematology, 2022-06-28)

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

Iacoboni García-Calvo, Gloria; Martinez-Cibrian, Nuria; Bailén, Rebeca; Corral, Lucia Lopez; Sanchez, Jose M.; Abrisqueta Costa, Pablo; Barba Suñol, Pere; Villacampa Javierre, Guillermo (Wiley, 2021-05)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

Dieras, Veronique; Cortés Castan, Javier; Patt, Debra; Wildiers, Hans; O’Shaughnessy, Joyce; Zamora Adelantado, Esther; Rugo, Hope (Springer, 2020-11)

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

Popat, Sanjay; Brustugun, Odd Terje; Cadranel, Jacques; Felip Font, Enriqueta; Garassino, Marina Chiara; Griesinger, Frank (Elsevier, 2021-07)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Browsing VHIO - Articles científics by Title

Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial

Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study

Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

Know Scientia

Guides and help

Go to...

Know Scientia

Guides and help

Go to...

Browsing VHIO - Articles científics by Title

Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial ﻿

Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice ﻿

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC ﻿

Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study ﻿

Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer ﻿

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test ﻿

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer ﻿

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study ﻿

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial ﻿

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program ﻿

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1 ﻿

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01) ﻿

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy ﻿

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma ﻿

Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study) ﻿

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura ﻿

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma ﻿

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma ﻿

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1 ﻿

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer ﻿

Know Scientia

Guides and help

Go to...

Know Scientia

Guides and help

Go to...

Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial

Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study

Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer